No annual revenue total was found in Avalyn Pharma Inc.'s SEC filings.
Avalyn Pharma Inc. (AVLN) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $413.5 million in cash and investments and $17.1 million in total debt.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$396.42M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AVLN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1540171
- Former names
- Genoa Pharmaceuticals, Inc. (until May 24, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 16, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 1, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 17, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | Jun 3, 2026 | Mar 31, 2026 |
All 63 Avalyn Pharma Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.